Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.69 |
| ▸ | RAB9A | P51151 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20804368 | 0.88 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5853157 | 0.85 | NPC1 (0.88) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4743393 | 0.83 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL28035640 | 0.83 | CYP2C9 (0.51) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2831462 | 0.83 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8817030 | 0.83 | LCK (0.65) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13720058 | 0.82 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL19577671 | 0.81 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL23135815 | 0.79 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3461361 | 0.79 | CA2 (0.68) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886718-B | Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound | 内蒙古工业大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-117886718-A | Preparation method of high-selectivity asymmetric urea compound and asymmetric urea compound | 内蒙古工业大学 | 2024-04-16 | — | — | CN | disclosed |
| US-20190284171-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2019-09-19 | — | — | US | disclosed |
| WO-2019073484-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284171-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | CBR3, CBR1, NOX3 | NPC1 934/4885RAB9A 3010/4885SMN1; SMN2 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.